{"id":"W2891251835","doi":"10.1200/jco.2018.36.15_suppl.10506","title":"Efficacy and safety results from a phase I/IIa study of dabrafenib in pediatric patients with <i>BRAF</i> V600–mutant relapsed refractory low-grade glioma.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"","keywords":"Medicine; Dabrafenib; Trametinib; Internal medicine; Adverse effect; Refractory (planetary science); Pilocytic astrocytoma; Glioma; Discontinuation; Oncology; Gastroenterology; Astrocytoma; Cancer; Cancer research","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001882955,0.0008739466,0.001283026,0.0002900829,0.0003390869,0.0006790487,0.000595518,0.0006262402,0.001852484],"category_scores_gemma":[0.00112671,0.000470439,0.001039638,0.0005464074,0.0005759765,0.0004665249,0.0003034576,0.001680375,0.0006432272],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001386419,"about_ca_system_score_gemma":0.001964996,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001798579,"about_ca_topic_score_gemma":0.005093738,"domain_scores_codex":[0.9992912,0.0003706435,0.00005862485,0.00009195371,0.0001015748,0.00008593503],"domain_scores_gemma":[0.9989785,0.0001566808,0.0003215811,0.00008559778,0.00009854264,0.0003592114],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4448352,0.04563439,0.1425486,0.002175562,0.005550617,0.002035415,0.001242374,0.006714934,0.1013596,0.0005054082,0.02057985,0.226818],"study_design_scores_gemma":[0.2517523,0.484973,0.2237306,0.0001777618,0.002469009,0.00396125,0.0003223616,0.00231264,0.01324025,0.0002701334,0.01670008,0.00009063917],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9913626,0.002734745,0.0003946407,0.0002744121,0.00003253131,0.00114952,0.002554445,0.00004102796,0.001456117],"genre_scores_gemma":[0.9843158,0.002762859,0.001782779,0.0007882915,0.00006179919,0.0009963209,0.008466658,0.00003130779,0.0007940775],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001882955,"threshold_uncertainty_score":0.01005924,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05443035417168518,"score_gpt":0.4115508320127396,"score_spread":0.3571204778410544,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}